Broekman, K. Esther
Hof, Marieke A. J.
Touw, Daan J.
Gietema, Jourik A.
Nijman, Hans W.
Lefrandt, Joop D.
Reyners, An K. L.
Jalving, Mathilde
Funding for this research was provided by:
Koninklijke Nederlandse Akademie van Wetenschappen
Article History
Received: 13 January 2020
Accepted: 28 February 2020
First Online: 7 March 2020
Compliance with ethical standards
:
: K.E. Broekman, M.A.J. Hof, D.J. Touw, J.D. Lefrandt and A.K.L. Reyners have no conflicts of interest to declare.J.A. Gietema: research grants to the institution of Roche, AbbVie, Siemens.H.W. Nijman: Clinical studies: Aduro, Vicinivax, Merck, DCPrime, AIMM. Founder and stock owner of Vicinivax.M. Jalving<b>:</b> Advisory Boards: Merck, BMS, Novartis, Pierre Fabre, Tesaro, AstraZeneca. Speakers’ fees: Sanofi. Clinical studies: BMS, AbbVie, Merck, Cristal Therapeutics. All fees paid to institution.
: The study protocol was approved by the Medical Ethics Committee of the University Medical Center Groningen (reference number 2013/505) and was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. The study was registered on ExternalRef removed, number NCT02312661.
: Written informed consent was obtained from all individual participants included in the study.